EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 656 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR Neighborhood Celebrates Teen’s Last Chemo Session With Socially-Distanced Parade March 27, 2020 Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade... September 7, 2021 Opinion: “We’ve been pushing for change for 20 years. We’re not... January 24, 2022 Coping With War and Cancer: How to Take Care of Your... March 11, 2022 Load more HOT NEWS CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... How Pelvic Floor Therapy Can Help People With Prostate Cancer and... Hospital Lockdown Prevents Breast Cancer Patient from Receiving Treatment for 3... Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients...
